文献速递胸部肿瘤放疗

肿瘤突变负荷及与放疗反应相关基因改变对非小细胞肺癌术后放疗结局的影响

Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-02-12

本研究分析89例接受术后放疗(PORT)的切除后非小细胞肺癌(NSCLC)患者,评估肿瘤突变负荷(TMB)及放疗敏感性相关基因突变对PORT结局的影响。结果显示放疗抵抗基因突变者PORT后局部区域失败显著增多(2年LRF率60% vs 11%,P<.001),而DDR基因突变者无LRF事件,高TMB与PORT后局部区域控制改善相关(HR 0.86,P=.01)。作者认为放疗抵抗基因改变者可能从PORT获益有限,高TMB和/或DDR基因改变者可能适合PORT及未来精准放疗策略,但需前瞻性研究验证。

要点

  • 放疗抵抗基因(KEAP1/NFE2L2/STK11/PIK3CA)突变者PORT后2年LRF率60% vs 无突变者11%(P<.001)。
  • DDR基因突变者PORT后无LRF事件,局部区域控制显著改善(P=.048)。
  • 高TMB与PORT后局部区域控制改善相关(HR 0.86,P=.01),ROC曲线下面积0.67-0.77。

核心结论

  • 数据提示放疗抵抗基因改变的患者可能从PORT获益有限,而高TMB和/或DDR基因改变的患者可能从PORT获益并适合未来精准放疗策略。
  • 需前瞻性研究验证这些发现。

研究设计与样本

  • 纳入接受和不接受PORT的切除后NSCLC且行肿瘤基因组分析的患者进行分析。
  • 分析89例接受PORT的NSCLC患者,2年LRF率为19%(95%CI 10%-27%)。
  • 采用Cox建模和受试者工作特征曲线(ROC)分析评估TMB与局部区域控制(LRC)的关系。

主要发现

  • 接受PORT患者中,放疗抵抗基因突变者(n=16[18%])较无突变者LRF显著增多(2年LRF率60% vs 11%,P<.001)。
  • 多因素分析中,放疗抵抗基因突变与PORT后LRF相关(HR 7.42,P<.001)。
  • DDR基因突变者(n=15[17%])PORT后LRC显著改善(P=.048)且无LRF事件。
  • 多因素分析中,较高TMB与PORT后LRC改善相关(HR 0.86,P=.01),TMB与PORT结局相关(ROC曲线下面积0.67-0.77)。
  • 这些基因组标志物在未接受PORT的患者中与LRF无类似关联。

局限性

  • 需前瞻性研究验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Postoperative radiation therapy (PORT) in resected non-small cell lung cancer (NSCLC) improves locoregional outcomes, but recent randomized data do not support its unselected use. We assessed if tumor mutational burden (TMB) and mutations in genes associated with radiation sensitivity can select patients for PORT. METHODS AND MATERIALS: Patients with resected NSCLC treated with and without PORT who underwent tumor genomic profiling were examined. The incidence of locoregional failures (LRFs) in patients with deleterious mutations in DNA damage response and repair (DDR) genes and genes associated with radiation resistance (KEAP1/NFE2L2/STK11/PIK3CA) were investigated. Cox modeling and receiver operating characteristic curve (ROC) analysis assessed the relationship between TMB and locoregional control (LRC). RESULTS: Eighty-nine patients with NSCLC treated with PORT were analyzed, with a 2-year LRF rate of 19% (95% confidence interval, 10%-27%). Among patients treated with PORT, those with mutations in radiation resistance genes (n = 16 [18%]) had significantly more LRFs than patients without mutations (2-year LRF rate: 60% vs 11%; P < .001). On multivariate analysis, radiation-resistance mutations were associated with LRF after PORT (hazard ratio, 7.42; P < .001). Patients with mutations identified in DDR genes (n = 15 [17%]) had significantly improved LRC (P = .048) and no LRF events after PORT. On multivariate analysis, a higher TMB was associated with improved LRC after PORT (hazard ratio, 0.86; P = .01), and TMB was associated with PORT outcomes (area under ROC curve, 0.67-0.77). These genomic markers were not similarly associated with LRF in patients not treated with PORT. CONCLUSIONS: The data suggest that patients with radiation-resistance gene alterations may derive minimal benefit from PORT, whereas patients with high TMB and/or alterations in DDR genes may benefit from PORT and be suited for future precision-RT strategies. Prospective studies are necessary to validate these findings.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Shaverdian N, Shepherd AF, Li X, et al. Effects of Tumor Mutational Burden and Gene Alterations Associated with Radiation Response on Outcomes of Postoperative Radiation Therapy in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 35157996. doi:10.1016/j.ijrobp.2022.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。